Summary
Thermo Fisher Scientific Inc. (TMO) filed an 8-K on September 10, 2020, to provide updated financial guidance during a virtual Analyst Meeting. The company significantly raised its third-quarter organic revenue growth expectations to 24%, a substantial increase from the previously forecasted 15%. This upward revision reflects strong business conditions and likely continued momentum from demand related to the COVID-19 pandemic. Furthermore, Thermo Fisher offered initial guidance for the fourth quarter, projecting organic revenue growth between 13% and 27%. For the full year 2020, the company now expects organic revenue growth to be in the range of 13% to 16%. Investors should note that these are estimates and actual results may vary due to ongoing market uncertainties.
Key Highlights
- 1Raised Q3 2020 organic revenue growth forecast from 15% to 24%.
- 2Provided initial Q4 2020 organic revenue growth estimate of 13% to 27%.
- 3Updated full-year 2020 organic revenue growth expectation to a range of 13% to 16%.
- 4The updates were shared by the CFO during a virtual Analyst Meeting.
- 5The company cautioned that actual results could differ from these estimates due to marketplace uncertainty.
- 6Organic revenue is defined as reported revenue excluding acquisition/divestiture impacts and foreign currency translation.